Melanocortin receptor agonist

Melanotan II

Melanotan II is a cyclic heptapeptide analog of alpha-MSH that the TGA says is not approved for use as a tanning agent in Australia.1,2 None of the sources cited gives a half-life measured in people.

Moderate evidenceGet the app

Level after one dose

Melanotan II after one dose: 50% at ~1 h, 25% at 2 h, 12.5% at 3 h.

Drawn from the half-life in the app's model, ~1 h. The model's figures

1

How Milligram users log it

Track your protocol with Milligram.

3%The 21st most tracked compound in Milligram: of people who track compounds in Milligram logged Melanotan II in the last 90 days.

Schedule

  1. Daily45%
  2. Every other day16%
  3. Twice a week27%
  4. Weekly11%
  5. Less often2%
Among people with three or more logged doses, by the average gap between their doses.

Logged doses

Half of people logged between 100 and 410 mcg per dose; the median was 250 mcg.

Each person's usual logged amount. The bar starts at zero; the shaded part is the middle half, the mark the median.

Tracked alongside

The share of people logging Melanotan II who also logged each.

From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.

Melanotan II (MT-II) is described by Dorr and colleagues as a lactam-bridged cyclic heptapeptide with the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10 alpha-MSH4-10-NH2.1 Peters and colleagues write that it "is a non-selective melanocortin-receptor agonist" whose effect on humans is "an increasing of skin pigmentation, producing of spontaneous penile erection and sexual stimulation".3 Hadley, of the University of Arizona College of Medicine, wrote in 2005 that its actions on sexual function "were discovered accidentally while studying the effects of the peptide and related analogs on human skin pigmentation (tanning)".4

The TGA states: "There are currently no products containing Melanotan II included in the Australian Register of Therapeutic Goods (ARTG) or approved for supply in Australia".2 In the United States, FDA lists melanotan II in its table "Bulk drug substances nominated but withdrawn" and names it among five substances for an advisory committee meeting "before the end of February 2027".5,6

The app's evidence badge is the app's own grade; the sources describe small trials of 3 to 20 men, a registered phase 2 trial that is recruiting, and case reports of harm.1,7,8,9,10

Weirath and Haskell-Luevano wrote in 2024 that there are "five melanocortin receptor subtypes" and that synthetic derivatives of alpha-MSH include "NDP-MSH (melanotan I), melanotan II (MTII), and SHU9119".11 Dorr and colleagues describe melanotan II as having "superpotent melanotropic activity in vitro".1 Hadley wrote that melanotan II "works at the level of the brain".4 In mice given 1 mg/kg intraperitoneally, Hatziieremia and colleagues write that the brain concentrations "confirmed the low penetrability of the peptide in mouse brain".13

4

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~1 h
Bioavailability
95%
Typical dose
100–500 mcg/day
Route
SubQ
Time to peak
~30 min

The figures in the table are the app's own, shown beside what the sources report.

Table 4.1Half-life and pharmacokinetics3 rows
ParameterApp's figureReported in the sources
Half-lifeAbout 1 hourNo human figure. In rats given 0.3 mg/kg intravenously, plasma levels showed biphasic disposition, and the terminal half-life (t1/2 beta) differed between the two assay methods.14 In mice given 1 mg/kg intraperitoneally, "clearance from plasma was rapid".13 Mallory and colleagues write "we suspect the half-life of MT II is long" without giving a measurement,19 and Hadley and Dorr describe melanotan I and II as two of several "superpotent, prolonged acting, enzymatically resistant" analogs.17
Bioavailability95% by subcutaneous injectionNo human figure. Lan and colleagues cite "a bioavailability of 4.6% in the rat" (the route is not stated in the summary text).15
Time to peakAbout 30 minutesNo figure reported. In 3 men, spontaneous erections were "intermittently experienced for 1-5 hours after MT-II dosing", an effect and not a concentration.1

The chart illustrates the app's own half-life and time to peak with the one dosing interval a trial reports; none of the sources cited reports a human concentration curve.1

Level over 1 weeks

Interval between doses

Level, as a share of the peak after one 250 mcg dose

As studied: every other day1. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).

An illustration from a pharmacokinetic model using a half-life of 1 hours. It is not a measured level or a suggested dose.

For comparison with a different compound, the label of bremelanotide (Vyleesi) gives a mean terminal half-life of "approximately 2.7 hours" after a single subcutaneous administration; that figure is not a melanotan II measurement.16

5

Human studies

The four published reports in the table below are from 1996 to 2000, all from groups at the University of Arizona, and enrolled men.1,7 The 2000 review describes the authors' own experience, so its 20 men are not necessarily separate from the men in the other reports.9 A 2026 systematic review of peptides for male sexual dysfunction (12 studies, 372 men) states that "Melanocortin receptor agonists" (in that review, PT-141/bremelanotide and melanotan II) "demonstrated the most consistent improvements in erectile function" and that "Overall, studies were limited by small sample sizes, heterogeneous populations, short follow-up durations, and a lack of comparative studies".18

Table 5.1Human studies5 rows
Study and yearDesignPeopleDose and lengthMain result
Dorr and colleagues, 19961Pilot phase I; single-blind, alternating day (saline or MT-II), placebo-controlled3 normal male volunteersStarted at 0.01 mg/kg subcutaneously, daily Monday to Friday for 2 consecutive weeks; 2 men escalated to 0.03 mg/kg, 1 to 0.025 mg/kgMild nausea at most dose levels; Grade II somnolence and fatigue in 1 of 2 men at 0.03 mg/kg; spontaneous erections for 1 to 5 hours after dosing; increased pigmentation in 2 men.
Wessells and colleagues, 19987Double-blind, placebo-controlled crossover; erections recorded by RigiScan for 6 hours10 men with erectile dysfunction of no known organic cause0.025 mg/kg against a vehicle placebo; erections recorded for 6 hoursClinically apparent erections in 8 of 10 men; mean duration of tip rigidity above 80% was 38.0 minutes with melanotan II and 3.0 with placebo (p=0.0045); nausea, stretching and yawning, and decreased appetite more frequent than with placebo, none requiring treatment.
Wessells and colleagues, 2000, Urology8Randomized, double-blind, placebo-controlled crossover; RigiScan for 6 hours and a desire questionnaire10 men with erectile dysfunction and organic risk factors0.025 mg/kg or vehicle, each given twice by subcutaneous injectionSubjectively reported erections after 12 of 19 injections against 1 of 21 placebo doses; mean tip rigidity above 80% lasted 45.3 minutes against 1.9 (P = 0.047); sexual desire higher; 4 of 19 injections followed by severe nausea.
Wessells and colleagues, 2000, Int J Impot Res9Review of the authors' own double-blind, placebo-controlled crossover experience; RigiScan for 6 hours20 men with psychogenic and organic erectile dysfunctionDose given only for the nausea figure: 0.025 mg/kgErection without sexual stimulation in 17 of 20 men; increased desire after 13 of 19 (68%) melanotan II doses against 4 of 21 (19%) placebo doses; 12.9% of subjects had severe nausea at 0.025 mg/kg.
Registry record NCT07437560, 202610Randomized 1:1, quadruple-masked, placebo-controlled phase 2 study with narrowband UV-B in stable nonsegmental vitiligo; recruitingEstimated enrollment 60 adultsMelanotan II or placebo plus phototherapy for 24 weeks; dose "administered per protocol"No results posted; primary outcome is change from baseline in Vitiligo Area Scoring Index total score at 24 weeks; lead sponsor Hudson Biotech (industry); the record calls it an "example trial", lists a single site in Shenzhen, China, and marks it not FDA-regulated.

Deeper analysis: Dorr and colleagues, Life Sciences, 1996

Dorr and colleagues of the University of Arizona gave 3 normal male volunteers subcutaneous melanotan II or saline on alternating days at a starting dose of 0.01 mg/kg, with two men escalated to 0.03 mg/kg and one to 0.025 mg/kg.1 The authors conclude: "These results demonstrate that MT-II has tanning activity in humans given only 5 low doses every other day by subcutaneous injection", and name 0.025 mg/kg/day as the recommended single dose for future phase I studies.1 Pigmentation increased in 2 of the 3 men, one man at 0.03 mg/kg had Grade II somnolence and fatigue, and the report describes mild nausea at most dose levels and spontaneous erections tied to a stretching and yawning complex.1 The PubMed record lists the research support as "Research Support, U.S. Gov't, P.H.S." and carries no conflict-of-interest statement; the summary text states no limitations, and its own description of the design is a single-blind study of 3 volunteers.1

Deeper analysis: Wessells and colleagues, 1998 and 2000

In the 1998 Journal of Urology crossover study, 8 of 10 men with erectile dysfunction of no known organic cause had clinically apparent erections, and the authors write that melanotan II "has manageable side effects at a dose of 0.025 mg./kg".7 In the 2000 Urology trial of 10 men with organic risk factors, the authors write that "The finding of increased sexual desire warrants further investigation of centrally acting agents on disorders of sexual desire", and report severe nausea after 4 of 19 injections.8 The review of 20 men gives the severe nausea figure as "12.9% of subjects" at 0.025 mg/kg, and its summary text does not state the denominator.9 The PubMed records list research support of the "Research Support, U.S. Gov't, P.H.S." type for the 1998 and 2000 Urology reports, plus "Research Support, Non-U.S. Gov't" for the 2000 Urology report, and carry no conflict-of-interest statement.7,8 Hadley and Dorr, of the University of Arizona College of Medicine, wrote in 2006 that melanotan I and II "have been patented and tested clinically".17

6

Doses reported in studies

The app's typical dose is 100 to 500 mcg/day; the trial reports give doses in mg/kg.1,8

Table 6.1Doses reported in studies5 rows
SourcePeopleDoseLengthResult noted
Dorr and colleagues, 199613 men, pilot trial0.01 to 0.03 mg/kg subcutaneously2 weeks, Monday to Friday, saline and melanotan II on alternating days (5 melanotan II doses)0.025 mg/kg/day recommended for future phase I studies.
Wessells and colleagues, 1998 and 20007,810 men and 10 men with erectile dysfunction0.025 mg/kgErections recorded for 6 hours; 2 injections each of melanotan II and vehicle (2000 trial)Erections in 8 of 10 men (1998) and after 12 of 19 injections (2000).
Nelson and colleagues, 2012, case report1239-year-old man6 mg subcutaneously, one injectionSingle dose; "six times the recommended starting dose per the patient"Systemic toxicity and rhabdomyolysis.
Mallory and colleagues, 2021, case report1955-year-old man2 mg subcutaneously to the abdomenSingle injectionIschemic priapism of 30 hours.
Vadner and Smith, 2026, case report2049-year-old man250 mcg, then 500 mcg, then 1000 mcg daily, each level for about 3 daysAbout 1 week, then melanotan I on a similar schedule5 melanomas in situ, with tanning bed use and testosterone use reported.

In the trials, nausea, stretching and yawning, and decreased appetite were reported more often with melanotan II than with placebo (1998), and severe nausea followed 4 of 19 injections (2000), as the studies table shows.7,8 Hadley wrote in 2005 of "minimal or no undesirable side effects", while the trials record severe nausea after some injections.4

Case reports of unregulated use

FDA's page states: "Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism".5 The TGA lists headache, nausea, vomiting, loss of appetite and facial redness as the most common side effects of melanotans, writes that "the most concerning one is the risk of serious skin cancers", and states that "With melanotan-II, there have been reports of increased moles and freckles, kidney dysfunction and swelling of the brain".21

Nelson and colleagues reported a 39-year-old man who injected 6 mg subcutaneously and was seen two hours later with sweating, anxiety, a heart rate of 130 beats per minute that peaked at 146, and diffuse muscle tremors.12 He spent 3 days in intensive care, his urine drug screen was positive for opiates, and the injected substance was confirmed as melanotan II by mass spectrometry.12 Peters and colleagues report a renal infarction "most likely attributed to Melanotan II" and write that a "thrombotic pharmacological influence and possible direct toxic effect on renal parenchyma must be considered"; the authors declare no conflict of interest.3

Mallory and colleagues describe a 55-year-old man with ischemic priapism of 30 hours after a 2 mg subcutaneous injection, who had used melanotan II for over 6 years and needed penoscrotal decompression surgery after bedside treatment failed.19 At 15 weeks he reported new-onset erectile dysfunction with rigidity 4/10 and corpora fibrosis on examination and had no response to PDE5 inhibitors, and the report states there was no concomitant other drug use.19 Dreyer and colleagues report low-flow priapism after an abdominal subcutaneous injection of "melanotan" (the type is not specified in the summary text), with erectile function not recovered at 4 weeks.22

Hjuler and Lorentzen reported a 20-year-old woman with Fitzpatrick skin type II and a melanoma on the gluteal region after a 3- to 4-week course of self-injections with melanotan II, with sunbed use, and the authors note that "the extent and types of adverse effects are unknown".23 Vadner and Smith (2026) report a 49-year-old man with five melanomas in situ who presented after 2 to 3 weeks of melanotan II, then melanotan I, with tanning bed use, and who also reported testosterone use; the authors write that "causality remains unproven" and that the melanomas may have been preexisting.20 Habbema and colleagues, reviewing unregulated use of melanotan I and II in 2017, state that "Four case reports have described melanomas emerging from existing moles either during or shortly after the use of melanotan" while "conclusive evidence linking these phenomena is lacking".24 Bonchev (2026) describes gingival and buccal pigmentation after 64 days of melanotan II injections, with the buccal pigmentation nearly gone at one month and gingival pigmentation persisting at three months.25 The patient had slight gingival pigmentation two years earlier and reported tobacco use and regular sunbed use, and the author writes that the finding "must be interpreted with caution".25

8

Bloodwork and markers

The app lists no markers to monitor for melanotan II.

FDA's page on bulk drug substances that may present significant safety risks, with content current as of 22 April 2026, carries melanotan II in the table headed "Bulk drug substances nominated but withdrawn", a list the page describes as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators", with the statement that compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities".5 FDA's advisory committee page, with content current as of 15 April 2026, says the committee will discuss "Cathelicidin (LL-37) GHK-Cu Dihexa acetate Melanotan II Mechano Growth Factor, Pegylated (PEG-MGF)" for possible inclusion on the 503A bulks list at a meeting before the end of February 2027.6 The text of FDA's list of substances nominated for the 503A bulks list, updated 14 May 2026, contains no entry for melanotan II in its three categories, and the introduction to FDA's briefing for the July 2026 meeting lists seven substance groups that do not include it.26,27 None of the FDA pages and documents cited states why melanotan II is on the committee agenda.5,6,26,27

The TGA states that melanotan II "is a prescription-only medicine in Australia and is not approved for use as a tanning agent".2 It reported that testing of 5 nasal spray bottles labelled "Pure Tans Triple Strength 30 MG" found an estimated 22 mg to 54 mg of melanotan II, based on the labelled volume of 20 mL per bottle.2 In January 2025 the TGA wrote: "Melanotan is not approved for sale or use as a tanning agent in Australia".21

Breindahl and colleagues analysed vials bought from three online shops: the melanotan II content ranged from 4.32 to 8.84 mg although each shop claimed 10 mg, and vials from two shops held unknown impurities of 4.1 to 5.9%, while impurities from the third shop were below the quantification limit.28 Deville and Charlier determined a purity of 30% in a powder from vials labelled "Melanotan II" submitted to a forensic laboratory.29

A related melanocortin receptor agonist, bremelanotide (Vyleesi), carries US approval from 2019 for "premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)", where the low sexual desire "causes marked distress or interpersonal difficulty" and is not due to a co-existing medical or psychiatric condition, problems with the relationship or the effects of a medication or drug substance; the label states that it is not indicated for HSDD in postmenopausal women or in men.16 The WADA 2026 Prohibited List text names no melanotan; its class S0 reads: "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use ... is prohibited at all times".30 The list does not state whether class S0 applies to melanotan II.30

The sources cited give no half-life, time to peak, bioavailability or plasma concentration of melanotan II measured in people, so the app's 1 hour, 30 minutes and 95% have no measured human figure beside them. The trials enrolled 3 to 20 men; the 1996 pilot ran 2 weeks, and in the 2000 Urology trial melanotan II and vehicle were each administered twice. The 2026 systematic review of peptides for male sexual dysfunction describes the evidence as limited by "small sample sizes, heterogeneous populations, short follow-up durations, and a lack of comparative studies".18 The registered vitiligo trial has posted no results.10 Case reports describe harm after use of unregulated products, and separate analyses of products sold online (Breindahl and colleagues, the TGA, Deville and Charlier) report contents that differ from labels.24,28,2,29 Vasylieva and colleagues (2026) note that melanotan II and related agents "remain accessible through unregulated markets, raising concerns about product quality, dosing variability, and incompletely characterized adverse effects".31

What is the half-life of melanotan II?

The app lists a half-life of about 1 hour for melanotan II, and none of the sources cited gives a half-life measured in people. In mice, "clearance from plasma was rapid", and bremelanotide, a different compound, has a label half-life of approximately 2.7 hours.13,16

What is melanotan II?

Melanotan II is a cyclic heptapeptide analog of alpha-MSH that Peters and colleagues call "a non-selective melanocortin-receptor agonist".1,3

Is melanotan II approved?

The TGA states that no products containing melanotan II are on the Australian Register of Therapeutic Goods or approved for supply in Australia.2 FDA's page lists melanotan II among substances nominated for compounding and withdrawn, and its advisory committee is to discuss it before the end of February 2027.5,6

Is melanotan II banned by WADA?

The WADA 2026 Prohibited List text does not name melanotan II.30 Its class S0 prohibits at all times any pharmacological substance not addressed elsewhere on the list and with no current approval by any governmental regulatory health authority for human therapeutic use, and the list does not state whether that applies to melanotan II.30

What is the difference between melanotan I and melanotan II?

Nelson and colleagues write that melanotan I "increases melanogenesis and eumelanin content to produce sunless tanning" while melanotan II also produces spontaneous penile erections and sexual stimulation.12

Is melanotan II the same as bremelanotide (PT-141)?

No: Hadley and Dorr describe PT-141 as "A new MTII analog", Ramez and colleagues list "PT-141/bremelanotide and Melanotan II" as the melanocortin receptor agonists they reviewed, and Nelson and colleagues describe bremelanotide as "a variation of Melanotan II".17,18,12 Bremelanotide has US approval from 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) that is not due to a co-existing medical or psychiatric condition, problems with the relationship or the effects of a medication or drug substance, its label states it is not indicated for HSDD in postmenopausal women or in men, and melanotan II has no such approval in the sources cited.16

What side effects have been reported with melanotan II?

In the 1998 trial, nausea, stretching and yawning, and decreased appetite were reported more often than with placebo; in the 2000 Urology trial, nausea and stretching/yawning were, and 4 of 19 injections were followed by severe nausea.7,8 Case reports describe rhabdomyolysis, renal infarction, priapism and melanoma, and FDA lists melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.12,3,5

13

References

  1. Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci 1996. PMID 8637402
  2. Therapeutic Goods Administration. Melanotan II tanning peptide products found to be inconsistently dosed. Safety advisory, 17 August 2026. TGA safety advisory
  3. Peters B, Hadimeri H, Wahlberg R, Afghahi H. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep 2020. PMID 31953620
  4. Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides 2005. PMID 15996790
  5. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Web page, content current as of 22 April 2026. FDA category 2 page
  6. US Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee. Web page, content current as of 15 April 2026. FDA advisory committee page
  7. Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol 1998. PMID 9679884
  8. Wessells H, Gralnek D, Dorr R, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000. PMID 11018622
  9. Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res 2000. PMID 11035391
  10. Hudson Biotech. Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo. ClinicalTrials.gov NCT07437560, record verified 2026-11. NCT07437560
  11. Weirath NA, Haskell-Luevano C. Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs). ACS Pharmacol Transl Sci 2024. PMID 39296259
  12. Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol 2012. PMID 23121206
  13. Hatziieremia S, Kostomitsopoulos N, Balafas V, Tamvakopoulos C. A liquid chromatographic/tandem mass spectroscopic method for quantification of the cyclic peptide melanotan-II. Plasma and brain tissue concentrations following administration in mice. Rapid Commun Mass Spectrom 2007. PMID 17610239
  14. Ugwu SO, Blanchard J, Nguyen LD, et al. A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats. Biopharm Drug Dispos 1994. PMID 7981427
  15. Lan EL, Ugwu SO, Blanchard J, et al. Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. J Pharm Sci 1994. PMID 7983590
  16. Cosette Pharmaceuticals, Inc. VYLEESI- bremelanotide injection. DailyMed, published 9 November 2026. DailyMed label
  17. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides 2006. PMID 16412534
  18. Ramez M, Mostafa MM, Mohamed H, et al. Peptides for male sexual dysfunction: a systematic review of emerging evidence. J Sex Med 2026. PMID 43002584
  19. Mallory CW, Lopategui DM, Cordon BH. Melanotan Tanning Injection: A Rare Cause of Priapism. Sex Med 2021. PMC7930850
  20. Vadner DJ, Smith S. Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use. JAAD Case Rep 2026. PMC13279914
  21. Therapeutic Goods Administration. Don't risk using tanning products containing melanotan. News article, 24 January 2025. TGA news article
  22. Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Rep 2019. PMID 30796078
  23. Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology 2014. PMID 24355990
  24. Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol 2017. PMID 28266027
  25. Bonchev A. Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report. Life (Basel) 2026. PMC12942211
  26. US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. List updated 14 May 2026. FDA 503A categories list
  27. US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23-24, 2026 (introduction). FDA briefing document
  28. Breindahl T, Evans-Brown M, Hindersson P, et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal 2015. PMID 24771717
  29. Deville M, Charlier C. Barbie drug identification: Not a child's play. J Forensic Sci 2024. PMID 39302005
  30. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026
  31. Vasylieva V, West A, Karpman E. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. Sex Med Rev 2026. PMID 42862021